Haemonetics (NYSE:HAE) Updates FY 2025 Earnings Guidance

Haemonetics (NYSE:HAE) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 4.500-4.700 for the period, compared to the consensus earnings per share estimate of 4.590. The company issued revenue guidance of $1.3 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion.

Analyst Upgrades and Downgrades

HAE has been the subject of a number of research analyst reports. StockNews.com upgraded Haemonetics from a “hold” rating to a “buy” rating in a research report on Friday. Barrington Research cut their price target on Haemonetics from $108.00 to $95.00 and set an “outperform” rating for the company in a report on Friday. JPMorgan Chase & Co. initiated coverage on Haemonetics in a report on Friday, December 6th. They set an “overweight” rating and a $116.00 price objective on the stock. JMP Securities lowered their target price on Haemonetics from $125.00 to $100.00 and set a “market outperform” rating for the company in a research report on Friday. Finally, Needham & Company LLC reduced their price target on shares of Haemonetics from $112.00 to $108.00 and set a “buy” rating on the stock in a research report on Friday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $101.67.

Haemonetics Trading Down 5.8 %

HAE stock opened at $59.34 on Friday. Haemonetics has a twelve month low of $59.09 and a twelve month high of $97.97. The stock has a market capitalization of $2.98 billion, a price-to-earnings ratio of 23.36, a price-to-earnings-growth ratio of 0.98 and a beta of 0.39. The company has a quick ratio of 2.09, a current ratio of 3.97 and a debt-to-equity ratio of 1.35. The firm’s fifty day simple moving average is $76.38 and its two-hundred day simple moving average is $78.41.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. As a group, analysts anticipate that Haemonetics will post 4.59 earnings per share for the current year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.